TLR4 and adenocarcinoma: The conjugated form of Toll-like receptor 4 (TLR4) with AuNPs was used as an adjunct therapy for human adenocarcinoma alveolar basal epithelial cells (A549 cells), which led to the downregulation of the expression of this receptor (Vyas and Goswami, 2019).